Pfizer Inc Edges Out Earnings Estimates

0
Pfizer Inc Edges Out Earnings Estimates
By Pfizer [Public domain], via Wikimedia Commons

Pfizer Inc. (NYSE:PFE) released the earnings results from its most recently completed quarter this morning before opening bell, posting adjusted earnings of 57 cents per share on $12.4 billion in revenue. Analysts had been expecting the drug maker to report earnings of 55 cents per share on $12.28 billion in revenue. In the same quarter last year, Pfizer posted $12.64 billion in revenue.

Play Quizzes 4

Net earnings for the third quarter were 42 cents, compared to 39 cents last year.

Morningstar Investment Conference: Fund Manager Highlights Personalized Medicine, Energy Security

Clint Carlson Far ViewHedge fund managers go about finding investment ideas in a variety of different ways. Some target stocks with low multiples, while others look for growth names, and still others combine growth and value when looking for ideas. Some active fund managers use themes to look for ideas, and Owen Fitzpatrick of Aristotle Atlantic Partners is Read More

Key metrics from Pfizer’s earnings report

Pfizer’s Global Established Pharmaceutical business reported an operational decline in revenues of 6% die to the loss of exclusivity and generic competition for the overactive bladder treatment Detrol LA, the erectile dysfunction drug Viagra and the Alzheimer’s treatment Aricept. The drug maker also ended the co-promotion collaboration for the COPD drug Spiriva in several markets. Revenue for Pfizer’s Global Innovative Pharmaceutical fell 4% operationally due to the end of the collaboration agreement for the arthritis drug Enbrel in Canada and the U.S.

The company’s Global Vaccines, Oncology and Consumer Healthcare division saw a 13% operational increase. That includes a 19% increase in operational revenues for global vaccines and higher sales of Prevnar. Revenues for Consumer Healthcare rose 4% operationally after the GERD drug Nexium 24HR and vitamin supplement growth in emerging markets. Pfizer’s Global Oncology revenues rose 17% due to strong demand for Xalkori and Inlyta.

Pfizer adjusts guidance

The company expects adjusted revenues to be between $48.7 billion and $49.7 billion, compared to the previous guidance of between $48.7 billion and $50.7 billion. Pfizer expects reported earnings per share to be between $1.50 and $1.59, compared to the previous guidance of between $1.47 and $1.62. The drug maker expects adjusted earnings per share to be between $2.23 and $2.27 for the full year, compared to the previous guidance of between $2.20 and $2.30 per share.

So far this year, Pfizer has repurchased $4.2 billion worth of its shares. Last week, the company’s board authorized an additional $11 billion worth of share repurchases. That’s in addition to the $1.3 billion in authorization under the current share repurchase program.

Updated on

Michelle Jones is editor-in-chief for ValueWalk.com and has been with the site since 2012. Previously, she was a television news producer for eight years. She produced the morning news programs for the NBC affiliates in Evansville, Indiana and Huntsville, Alabama and spent a short time at the CBS affiliate in Huntsville. She has experience as a writer and public relations expert for a wide variety of businesses. Email her at Mjones@valuewalk.com.
Previous article The Secret Words Clients Love to Hear
Next article Guy Spier: Reduce the Number of Decisions

No posts to display